| Literature DB >> 35798523 |
Ellen de Bock1, Mando D Filipe2, Roger K J Simmermacher3, A Christiaan Kroese4, Menno R Vriens2, Milan C Richir2.
Abstract
OBJECTIVES: Patients with COVID-19 may be asymptomatic and are able to transmit COVID-19 during a surgical procedure, resulting in increased pressure on healthcare and reduced control of COVID-19 spread. There remains uncertainty about the implementation of preoperative screening for COVID-19 in asymptomatic surgical patients. Therefore, this study aims to determine the prevalence of preoperative COVID-19, confirmed by reverse transcriptase PCR (RT-PCR), in asymptomatic patients.Entities:
Keywords: COVID-19; infection control; surgery
Mesh:
Year: 2022 PMID: 35798523 PMCID: PMC9263349 DOI: 10.1136/bmjopen-2021-058389
Source DB: PubMed Journal: BMJ Open ISSN: 2044-6055 Impact factor: 3.006
Figure 1Flow chart showing literature search and study selection with 27 relevant studies included. PRISMA, Preferred Reporting Items for Systematic Reviews and Meta-Analyses; RT-PCR, reverse transcriptase PCR.
Characteristics of the included studies on preoperative COVID-19 screening
| Author | Country | Study period in 2020 | No of asymptomatic patients | Surgical discipline | Evaluated screening method | Reference screening method | TP | FP | TN | FN | Prevalence of COVID-19 (%) | No days symptom- screening before hospital admission |
| Ap Dafydd | UK | April 1 - May 31 | 240 | Oncology | Symptom screening and chest CT | RT-PCR | 1 | 8 | 230 | 1 | 0.83 | NR |
| Bloom | USA | March 30 - April 12 | 84 | Urgent, different disciplines | Symptom screening | RT-PCR | 0 | 0 | 81 | 3 | 3.57 | ≤2 |
| Blumberg | USA | March 26 - June 13 | 1161 | Orthopaedic | Symptom screening | RT-PCR | 0 | 0 | 1155 | 6 | 0.52 | ≤3 |
| Castellvi | Spain | April 15 - May 4 | 171 | Oncology | Symptom screening | RT-PCR | 0 | 0 | 171 | 0 | 0.00 | ≤2 |
| Coatsworth | Australia | June 2 - July 17 | 3010 | Different divisions | Symptom screening | RT-PCR | 0 | 0 | 3010 | 0 | 0.00 | NR |
| Ferrari | Italy | March 16 - April 17 | 41 | Oncology | Symptom screening | RT-PCR | 0 | 0 | 41 | 0 | 0.00 | ≤7 |
| Gruskay | USA | April 5 - April 24 | 81 | Orthopaedic | Symptom screening | RT-PCR | 0 | 0 | 74 | 7 | 8.64 | NR |
| Guerlain | France | March 25th and May 12th | 477 | Oncology | Symptom screening and chest CT | RT-PCR | NR | NR | 459 | 18 | 3.77 | 0 |
| Gümüs | Turkey | April 20 - May 31 | 218 | Different divisions | Symptom screening and chest CT | RT-PCR | 1 | 12 | 203 | 2 | 1.38 | NR |
| Gupta | India | April 18 - May 28 | 764 | Different divisions | Symptom screening | RT-PCR or True-NAT RT-PCR | 0 | 0 | 762 | 2 | 0.26 | 0 |
| Hendrickson | USA | April 7 - May 21 | 1997 | Different divisions | Symptom screening | RT-PCR | 0 | 0 | 1990 | 7 | 0.35 | 0 |
| Kannan | India | July 16 - August 31 | 413 | Retinal | Symptom screening | RT-PCR | 0 | 0 | 404 | 9 | 2.18 | 0 |
| Kavanagh | Ireland | March 1 - June 30 | 156 | Otolaryngology | Symptom screening | RT-PCR | 0 | 0 | 156 | 0 | 0.0 | 0 |
| Lopes | Brazil | May – October | 1636 | Oncology | Symptom screening | RT-PCR | 0 | 0 | 1534 | 102 | 6.23 | five and 1 |
| Myles | Australia | July 15 -August 31 | 4965 | Different divisions | Symptom screening | RT-PCR | 0 | 0 | 4961 | 4 | 0.08 | five and 0 |
| Nekkanti | India | April 18 - June 20 | 262 | Oncology | Symptom screening | RT-PCR | 0 | 0 | 241 | 21 | 8.02 | ≤2 |
| Patkar | India | April - September | 2108 | Oncology | Symptom screening | RT-PCR | 0 | 0 | 1908 | 200 | 9.49 | ≤2 |
| Puylaert | The Netherlands | March 20 - April 24 | 1224 | Different divisions | Symptom screening and chest CT | RT-PCR | 4 | 4 | 1206 | 10 | 1.14 | 0 |
| Ralhan | India | April 19 - May 29 | 64 | Cardiac | Symptom screening | RT-PCR | 0 | 0 | 63 | 1 | 1.56 | 0 |
| Singer | USA | April 7 - May 21 | 4743 | Different divisions | Symptom screening | RT-PCR | 0 | 0 | 4737 | 6 | 0.13 | ≤2 |
| Singh | India | September - December | 218 | Ophthalmology | Symptom screening | RT-PCR | 0 | 0 | 202 | 16 | 7.34 | 0 |
| Shah | USA | March 1 - April 30 | 625 | Different divisions | Symptom screening and chest CT | RT-PCR | 0 | 19 | 605 | 1 | 0.16 | ≤7 |
| Tilmans | France | March 2 - April 10 | 30 | Different divisions | Symptom screening | RT-PCR | 0 | 0 | 30 | 0 | 0.00 | 0 |
| Urban | USA | March 23 - April 17 | 21 | Otolaryngology | Symptom screening | RT-PCR | 0 | 0 | 20 | 1 | 4.76 | ≤4 |
| Cwalinksi | Poland | June – July | 94 | Different divisions | Symptom screening | RT-PCR | 0 | 0 | 94 | 0 | 0.00 | NR |
| Zangrilli | USA | May 1 - July 21 | 2329 | Orthopaedics | Symptom screening | RT-PCR | 0 | 0 | 2324 | 5 | 0.21 | NR |
| Zahra | UK | May 4 - June 15 | 124 | Orthopaedic | Symptom screening | RT-PCR | 0 | 0 | 121 | 3 | 2.42 | ≤5 |
FN, false-negative; FP, false-positive; NR, not reported; RT-PCR, real time reverse transcriptase PCR; TN, true negative; TP, true positive.
Figure 2Forest plot of the prevalence (%) of asymptomatic COVID-19 positive patients in the preoperative setting.
Average PPV, NPV, FP and FN applied to a hypothetical cohort of 100 000 patients with varying COVID-19 prevalence in asymptomatic preoperative patients tested with RT-PCR
| COVID-19 prevalence (%) | PPV (%) | NPV (%) | FP (N) | FN (N) |
| 10.00 | 90.9 | 98.9 | 900 | 1000 |
| 9.49* | 90.4 | 99.0 | 905 | 949 |
| 5.00 | 82.6 | 99.5 | 950 | 500 |
| 1.00 | 47.6 | 99.9 | 990 | 100 |
| 0.76† | 40.8 | 99.9 | 992 | 76 |
| 0.00‡ | 0 | 100 | 1000 | 0 |
*The highest COVID-19 prevalence in our study population in the included studies.
†COVID-19 positive prevalence on average of the 27 included studies in this meta-analysis.
‡The lowest COVID-19 prevalence in our study population in the included studies.
FN, false-negative; FP, false-positive; N, number; NPV, negative predictive value; PPV, positive predictive value; RT-PCR, real time reverse transcriptase PCR.